Commercial Channels

Diligent Health Solutions banks on experienced management

A marketing challenge: how to make more adults aware of anti-bacterial booster shots

Signs up Bayer Health for pulmonary hypertension and MS

Programs provide copay and other financial assistance

Spending on drug promotion rose—but not at the rate of pharma sales growth

Sandoz and Pear Therapeutics tackle opioid use disorder

List includes 25 orphan drugs; there were also seven additional biosimilars

Nearly a million US citizens live with HIV, a virus that still lacks a curative therapy

Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals

$360-million settlement involved assistance funneled through a charity

New Cardinal Health survey sees the profession adjusting to value-based care

Now a national provider, Senderra’s new dispensing location is in Morrisville, NC

New survey finds weaknesses in patient privacy, funding oversight

The battle between pharma and PBMs over copays intensifies

Most pharmacists want more time to counsel patients; most are concerned with drug reimbursement issues

Integrating pharma communications with electronic health-record systems brings value to patients and providers

Biologics, RxCrossroads units will retain their identity

$700,000 fine to benefit New York State residents

Not compensating for speaker programs and sponsored meetings has affected marketing, says the firm

Devices modeled after the BD UltraSafe units

Company will now have three operational centers across the US

Virtual assistants delivering guidance from Accenture’s Intelligent Patient Platform

Electronic benefits verification (eBV) combines with patient access services

Platform will operate within IBM’s HyperLedger blockchain technology

The orphan drug will reach patients through a limited-distribution network of specialty pharmacies

The year-old-plus litigation highlights the value of customer master data

Alliance for Regenerative Medicine tries to rationalize how payers address economic value

Rare diseases are hard to treat; supporting the patient can be even more challenging

Leading US provider will produce 70 million doses in next several months